Top

Published in:

Open Access 01-12-2017 | Case report

Langerhans cell histiocytosis of the maxillae in a child treated only with chemotherapy: a case report

Authors: Angela Pia Cazzolla, Giuseppe Troiano, Khrystyna Zhurakivska, Eugenio Maiorano, Gianfranco Favia, Maria Grazia Lacaita, Giuseppe Marzo, Franca Dicuonzo, Stefano Andresciani, Lorenzo Lo Muzio

Published in: Journal of Medical Case Reports | Issue 1/2017

Abstract

Background

Langerhans cell histiocytosis is a sporadic disease caused by an uncontrolled pathogenic clonal proliferation of dendritic cells that have Langerhans cell characteristics. New treatment protocols provided by the HISTSOC-LCH-III (NCT00276757) trial show an improvement in the survival of children with langerhans cell histiocytosis.

Case presentation

We report a case of Langerhans cell histiocytosis, which presented as an osteolytic lesion of the left pre-maxillae enclosing the deciduous incisor and canine in a 7-month-old white Italian boy. He was treated with chemotherapy. He achieved complete remission after 7 months and after 24 months no signs of recurrence were observed.

Conclusions

As a result of this treatment, anesthetic sequelae and loss of teeth were avoided; in addition, we prevented a loss of the vertical dimension of occlusion.

Laman JD, Leenen PJ, Annels NE, Hogendoorn PC, Egeler RM. Langerhans-cell histiocytosis ‘insight into DC biology’. Trends Immunol. 2003;24:190–6.CrossRefPubMed

PDQ Pediatric Treatment Editorial Board. Langerhans Cell Histiocytosis Treatment (PDQ®): Health Professional Version. In: PDQ Cancer Information Summaries. Bethesda: National Cancer Institute; 2002.

Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr. 2001;138:728–34.CrossRefPubMed

Gadner H, Grois N, Potschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008;111:2556–62.CrossRefPubMed

Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121:5006–14.CrossRefPubMed

Badalian-Very G, Vergilio JA, Degar BA, Rodriguez-Galindo C, Rollins BJ. Recent advances in the understanding of Langerhans cell histiocytosis. Br J Haematol. 2012;156:163–72.CrossRefPubMed

Arico M. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy. Br J Haematol. 2016;173:663–70.CrossRefPubMed

Geissmann F, Lepelletier Y, Fraitag S, et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood. 2001;97:1241–8.CrossRefPubMed

Valladeau J, Caux C, Lebecque S, Saeland S. Langerin: a new lectin specific for Langerhans cells induces the formation of Birbeck granules. Pathol Biol (Paris). 2001;49:454–5.CrossRef

10.

Harrist TJ, Bhan AK, Murphy GF, et al. Histiocytosis-X: in situ characterization of cutaneous infiltrates with monoclonal antibodies. Am J Clin Pathol. 1983;79:294–300.CrossRefPubMed

11.

Schuler G, Stingl G, Aberer W, Stingl-Gazze LA, Honigsmann H, Wolff K. Histiocytosis X cells in eosinophilic granuloma express Ia and T6 antigens. J Invest Dermatol. 1983;80:405–9.CrossRefPubMed

12.

Mizumoto N, Takashima A. CD1a and langerin: acting as more than Langerhans cell markers. J Clin Invest. 2004;113:658–60.CrossRefPubMedPubMedCentral

13.

Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol. 2007;7:19–30.CrossRefPubMed

14.

Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol. 2006;311:17–58.PubMed

15.

Fleming MD, Pinkus JL, Fournier MV, et al. Coincident expression of the chemokine receptors CCR6 and CCR7 by pathologic Langerhans cells in Langerhans cell histiocytosis. Blood. 2003;101:2473–5.CrossRefPubMed

16.

Annels NE, Da Costa CE, Prins FA, Willemze A, Hogendoorn PC, Egeler RM. Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med. 2003;197:1385–90.CrossRefPubMedPubMedCentral

17.

Yu RC, Morris JF, Pritchard J, Chu TC. Defective alloantigen-presenting capacity of ‘Langerhans cell histiocytosis cells’. Arch Dis Child. 1992;67:1370–2.CrossRefPubMedPubMedCentral

18.

Senechal B, Elain G, Jeziorski E, et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med. 2007;4:e253.CrossRefPubMedPubMedCentral

19.

Allen CE, Li L, Peters TL, et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 2010;184:4557–67.CrossRefPubMedPubMedCentral

20.

Ginhoux F, Merad M. Ontogeny and homeostasis of Langerhans cells. Immunol Cell Biol. 2010;88:387–92.CrossRefPubMed

21.

Badalian-Very G, Vergilio JA, Fleming M, Rollins BJ. Pathogenesis of Langerhans cell histiocytosis. Annu Rev Pathol. 2013;8:1–20.CrossRefPubMed

22.

Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014;124:3007–15.CrossRefPubMedPubMedCentral

23.

Nelson DS, van Halteren A, Quispel WT, et al. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer. 2015;54:361–8.CrossRefPubMed

24.

Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211:669–83.CrossRefPubMedPubMedCentral

25.

Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. J Clin Oncol. 2015;33:411–8.CrossRefPubMed

26.

Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373:726–36.CrossRefPubMedPubMedCentral

27.

Heritier S, Jehanne M, Leverger G, et al. Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. JAMA Oncol. 2015;1:836–8.CrossRefPubMed

28.

Bechan GI, Egeler RM, Arceci RJ. Biology of Langerhans cells and Langerhans cell histiocytosis. Int Rev Cytol. 2006;254:1–43.CrossRefPubMed

29.

McClain KL. Drug therapy for the treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother. 2005;6:2435–41.CrossRefPubMed

30.

Madrigal-Martinez-Pereda C, Guerrero-Rodriguez V, Guisado-Moya B, Meniz-Garcia C. Langerhans cell histiocytosis: literature review and descriptive analysis of oral manifestations. Med Oral Patol Oral Cir Bucal. 2009;14:E222–8.PubMed

31.

Hernandez-Juyol M, Boj-Quesada JR, Gallego MS. Oral manifestations of Langerhans cell histiocytosis. Case study of a two-year-old boy. Med Oral. 2003;8:19–25.PubMed

32.

Milian MA, Bagan JV, Jimenez Y, Perez A, Scully C, Antoniades D. Langerhans’ cell histiocytosis restricted to the oral mucosa. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91:76–9.CrossRefPubMed

33.

Stewart JC, Regezi JA, Lloyd RV, McClatchey KD. Immunohistochemical study of idiopathic histiocytosis of the mandible and maxilla. Oral Surg Oral Med Oral Pathol. 1986;61:48–53.CrossRefPubMed

34.

Rees J, Paterson AW. Langerhans cell histiocytosis in an adult. Br J Oral Maxillofac Surg. 2009;47:52–3.CrossRefPubMed

35.

Haupt R, Minkov M, Astigarraga I, et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013;60:175–84.CrossRefPubMed

Title: Langerhans cell histiocytosis of the maxillae in a child treated only with chemotherapy: a case report
Authors: Angela Pia Cazzolla
Giuseppe Troiano
Khrystyna Zhurakivska
Eugenio Maiorano
Gianfranco Favia
Maria Grazia Lacaita
Giuseppe Marzo
Franca Dicuonzo
Stefano Andresciani
Lorenzo Lo Muzio
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Journal of Medical Case Reports / Issue 1/2017
Electronic ISSN: 1752-1947
DOI: https://doi.org/10.1186/s13256-017-1286-3

At a glance: The STEP trials

Springer Medicine

Langerhans cell histiocytosis of the maxillae in a child treated only with chemotherapy: a case report

Abstract

Background

Case presentation

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Myxoma of the kidney – an unusual benign renal tumor: a case report

Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report

Multilevel lumbar spine infection due to poor dentition in an immunocompetent adult: a case report

Unexpected extrapyramidal symptoms and pulmonary aspergillosis in exertional heatstroke with fulminant liver failure: a case report

Possible gasoline-induced chronic liver injury due to occupational malpractice in a motor mechanic: a case report

Hemoglobin Himeji and inconsistent hemoglobin A1c values: a case report